SanBio Co (JP:4592) has released an update.
SanBio Co., Ltd. announced that the Fourth Pharmaceutical Affairs Council meeting of FY2024 included a report on the approved regenerative medicine product AKUUGO🄬🄬, a stem cell therapy for brain injury, which received conditional and time-limited approval. No significant discussion occurred regarding the report’s contents. SanBio, a leader in regenerative cell business, continues to focus on R&D for central nervous system disorders.
For further insights into JP:4592 stock, check out TipRanks’ Stock Analysis page.
